Key result
Adding ramipril to conventional treatment in heart failure patients after myocardial infarction was cost-effective, with an incremental cost of 1550.10 per life-year gained over 3.8 years.
Why the study?
Is adding ramipril to conventional treatment cost-effective in patients with heart failure after myocardial infarction?
Is adding ramipril to conventional treatment cost-effective in patients with heart failure after myocardial infarction?
The addition of ramipril to conventional treatment in patients with heart failure after myocardial infarction is highly cost-effective within the Spanish National Health System.
Supports ramipril addition as cost-effective in Spanish post-MI HF; extends AIRE efficacy data with economic analysis.
AIMS: To estimate the cost-effectiveness of adding ramipril to conventional treatment in patients with heart failure after myocardial infarction from the perspective of the Spanish National Health System. METHODS AND RESULTS: A retrospective analysis of the AIRE study was made, using previously published data from the clinical trial combined with local Spanish resource and cost data. A typical rehospitalisation for a heart failure episode would last an average of 11.6 days with an average cost of 350.80 per day. The incremental cost of ramipril per life-year gained in the baseline case was 1550.10 after 3.8 years of follow-up. Sensitivity analysis showed that the basic conclusions were robust in spite of extreme variations in the values of the key parameters of the model. CONCLUSION: The use of ramipril in addition to conventional treatment in heart failure patients after myocardial infarction is cost-effective both according to currently accepted international standards of what constitutes a cost-effective intervention and also indirectly by comparing the results with similar pharmaceutical products financed under the Spanish National Health System.
No takes yet. Share an insight, caveat, or question.
Hart et al. (2002) studied Heart failure after myocardial infarction. Ramipril vs. Conventional treatment was evaluated on Incremental cost per life-year gained. Adding ramipril to conventional treatment in heart failure patients after myocardial infarction was cost-effective, with an incremental cost of 1550.10 per life-year gained over 3.8 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: